Constantinos E Alifieris1,2,3, Kyriakos Orfanakos4, Aristina Papanota4, George P Stathopoulos5, Nikolaos Sitaras4, Dimitrios T Trafalis4,5. 1. Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, 75 Μikras Asias (Building 16), Goudi,, 11527, Athens, Greece. kalifier@med.uoa.gr. 2. Department of Medical Oncology, "Henry Dunant" Hospital Center, Athens, Greece. kalifier@med.uoa.gr. 3. Department of Surgery, Agia Olga Hospital, Athens, Greece. kalifier@med.uoa.gr. 4. Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, 75 Μikras Asias (Building 16), Goudi,, 11527, Athens, Greece. 5. Department of Medical Oncology, "Henry Dunant" Hospital Center, Athens, Greece.
Abstract
PURPOSE: This is a single-center uncontrolled retrospective study to evaluate the efficacy and safety of the biosimilar epoetin zeta after approval in chemotherapy-induced anemia (CIA). METHODS: Patients screened were >18 years old suffering from solid malignancies and CIA with Hg ≤10 or <11 g/dl if symptomatic anemia. Patients had measurable disease by TNM and Eastern Cooperative Oncology Group (ECOG). Patients were treated for at least 12 weeks and the primary endpoint was to determine the incidence of blood transfusions, and secondarily, the overall safety and efficacy defined as ≥1 g/dl rise in Hb concentration or ≥40,000 cells/μl rise in reticulocyte count. Quality of life was assessed with ECOG performance status (PS) and functional assessment of cancer therapy-anemia (FACT-An) score. RESULTS: 1287 patients with median Hb 9.3 g/dl (range 8.3-10.6) were enrolled and included in the evaluation. Median age was 63 years (range 33-78). 74% of patients were stage III/IV. Patients received epoetin zeta subcutaneously at fixed 40,000-IU once weekly. Blood transfusions were given in 178 patients (13.8%; 95% CI 11.9-15.6%). Appropriate response was observed in 79% patients by week 4, 87% by week 8, and 91% by week 12. A mean Hb increase of 2.5 g/dl was observed by week 12 which correlated with an improvement in PS and Fact-An score. Thrombotic events occurred in 5.2% (95% CI 3.4-7.1%) of patients. CONCLUSIONS: Epoetin zeta is effective in palliation and treatment of CIA in patients with solid tumors. Overall, it is well tolerated and safe even in patients with increased disease burden.
PURPOSE: This is a single-center uncontrolled retrospective study to evaluate the efficacy and safety of the biosimilar epoetin zeta after approval in chemotherapy-induced anemia (CIA). METHODS:Patients screened were >18 years old suffering from solid malignancies and CIA with Hg ≤10 or <11 g/dl if symptomatic anemia. Patients had measurable disease by TNM and Eastern Cooperative Oncology Group (ECOG). Patients were treated for at least 12 weeks and the primary endpoint was to determine the incidence of blood transfusions, and secondarily, the overall safety and efficacy defined as ≥1 g/dl rise in Hb concentration or ≥40,000 cells/μl rise in reticulocyte count. Quality of life was assessed with ECOG performance status (PS) and functional assessment of cancer therapy-anemia (FACT-An) score. RESULTS: 1287 patients with median Hb 9.3 g/dl (range 8.3-10.6) were enrolled and included in the evaluation. Median age was 63 years (range 33-78). 74% of patients were stage III/IV. Patients received epoetin zeta subcutaneously at fixed 40,000-IU once weekly. Blood transfusions were given in 178 patients (13.8%; 95% CI 11.9-15.6%). Appropriate response was observed in 79% patients by week 4, 87% by week 8, and 91% by week 12. A mean Hb increase of 2.5 g/dl was observed by week 12 which correlated with an improvement in PS and Fact-An score. Thrombotic events occurred in 5.2% (95% CI 3.4-7.1%) of patients. CONCLUSIONS:Epoetin zeta is effective in palliation and treatment of CIA in patients with solid tumors. Overall, it is well tolerated and safe even in patients with increased disease burden.
Entities:
Keywords:
Anemia; Biosimilar; Chemotherapy; Epoetin zeta; Erythropoietin; Quality of life
Authors: Enrico Cortesi; Pere Gascón; David Henry; Timothy Littlewood; Robert Milroy; Paolo Pronzato; Uwe Reinhardt; Daniel Shasha; Nicholas Thatcher; Peter Wilkinson Journal: Oncology Date: 2005 Impact factor: 2.935
Authors: Thomas E Witzig; Peter T Silberstein; Charles L Loprinzi; Jeff A Sloan; Paul J Novotny; James A Mailliard; Kendrith M Rowland; Steven R Alberts; James E Krook; Ralph Levitt; Roscoe F Morton Journal: J Clin Oncol Date: 2004-09-27 Impact factor: 44.544
Authors: George M Rodgers; Pamela Sue Becker; Morey Blinder; David Cella; Asher Chanan-Khan; Charles Cleeland; Peter F Coccia; Benjamin Djulbegovic; Jeffrey A Gilreath; Eric H Kraut; Ursula A Matulonis; Michael M Millenson; Denise Reinke; Joseph Rosenthal; Rowena N Schwartz; Gerald Soff; Richard S Stein; Gordana Vlahovic; Alva B Weir Journal: J Natl Compr Canc Netw Date: 2012-05 Impact factor: 11.908